NUP160
Basic information
Region (hg38): 11:47778087-47848555
Links
Phenotypes
GenCC
Source:
- nephrotic syndrome, type 19 (Strong), mode of inheritance: AR
- familial idiopathic steroid-resistant nephrotic syndrome (Supportive), mode of inheritance: AD
- nephrotic syndrome, type 19 (Limited), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Nephrotic syndrome, type 19 | AR | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Renal | 30179222 |
ClinVar
This is a list of variants' phenotypes submitted to
- not provided (2 variants)
- Nephrotic syndrome, type 19 (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the NUP160 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 34 | 43 | ||||
missense | 143 | 156 | ||||
nonsense | 2 | |||||
start loss | 0 | |||||
frameshift | 2 | |||||
inframe indel | 1 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 3 | 8 | 3 | 14 | ||
non coding | 27 | 35 | ||||
Total | 3 | 0 | 148 | 70 | 18 |
Highest pathogenic variant AF is 0.000112
Variants in NUP160
This is a list of pathogenic ClinVar variants found in the NUP160 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
11-47779146-C-G | Uncertain significance (May 25, 2022) | |||
11-47779150-T-G | not specified | Uncertain significance (Dec 14, 2023) | ||
11-47779164-CCT-C | Nephrotic syndrome, type 19 | Pathogenic (-) | ||
11-47779171-T-C | NUP160-related disorder | Benign (Jan 25, 2024) | ||
11-47779197-A-G | NUP160-related disorder | Uncertain significance (May 19, 2022) | ||
11-47780327-GA-G | Likely benign (Jun 13, 2023) | |||
11-47780345-C-T | not specified | Uncertain significance (Apr 28, 2022) | ||
11-47780379-A-G | Likely benign (Jul 15, 2022) | |||
11-47780382-T-C | Likely benign (Aug 24, 2023) | |||
11-47780399-T-C | not specified | Uncertain significance (Jan 24, 2024) | ||
11-47780401-G-A | not specified | Uncertain significance (Aug 08, 2023) | ||
11-47780406-G-A | NUP160-related disorder | Benign (Jan 15, 2024) | ||
11-47780409-T-C | Likely benign (Apr 30, 2023) | |||
11-47780423-T-C | not specified | Uncertain significance (May 14, 2024) | ||
11-47780426-G-C | Uncertain significance (Jul 21, 2022) | |||
11-47783059-T-C | Likely benign (Sep 10, 2023) | |||
11-47783064-T-TATAC | Likely benign (Oct 21, 2022) | |||
11-47783075-C-T | Uncertain significance (Oct 17, 2022) | |||
11-47783113-T-C | Uncertain significance (Jun 13, 2022) | |||
11-47783141-C-T | not specified | Uncertain significance (Dec 14, 2023) | ||
11-47783161-T-G | not specified | Uncertain significance (Dec 21, 2021) | ||
11-47783169-T-G | not specified | Uncertain significance (Oct 29, 2024) | ||
11-47783179-A-C | Uncertain significance (Dec 01, 2023) | |||
11-47783196-C-G | Nephrotic syndrome, type 19 | Uncertain significance (Jun 26, 2024) | ||
11-47783212-G-A | Likely benign (Dec 20, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
NUP160 | protein_coding | protein_coding | ENST00000378460 | 36 | 70469 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.00000678 | 1.00 | 125647 | 0 | 101 | 125748 | 0.000402 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 1.04 | 698 | 780 | 0.895 | 0.0000405 | 9336 |
Missense in Polyphen | 146 | 198.49 | 0.73555 | 2397 | ||
Synonymous | 0.213 | 274 | 279 | 0.984 | 0.0000135 | 2764 |
Loss of Function | 6.08 | 27 | 88.8 | 0.304 | 0.00000475 | 1033 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000686 | 0.000686 |
Ashkenazi Jewish | 0.00190 | 0.00189 |
East Asian | 0.000275 | 0.000272 |
Finnish | 0.000144 | 0.000139 |
European (Non-Finnish) | 0.000338 | 0.000334 |
Middle Eastern | 0.000275 | 0.000272 |
South Asian | 0.000564 | 0.000555 |
Other | 0.000178 | 0.000163 |
dbNSFP
Source:
- Function
- FUNCTION: Involved in poly(A)+ RNA transport. {ECO:0000269|PubMed:11684705}.;
- Pathway
- RNA transport - Homo sapiens (human);tRNA processing;Disease;Signal Transduction;Gene expression (Transcription);Regulation of HSF1-mediated heat shock response;Metabolism of carbohydrates;Rev-mediated nuclear export of HIV RNA;Late Phase of HIV Life Cycle;HIV Life Cycle;Interactions of Rev with host cellular proteins;Host Interactions of HIV factors;HIV Infection;snRNP Assembly;Vpr-mediated nuclear import of PICs;SUMOylation of DNA damage response and repair proteins;Transport of Ribonucleoproteins into the Host Nucleus;Viral Messenger RNA Synthesis;Export of Viral Ribonucleoproteins from Nucleus;SUMOylation of chromatin organization proteins;Influenza Viral RNA Transcription and Replication;Cellular responses to stress;SUMOylation of RNA binding proteins;Post-translational protein modification;SUMOylation of DNA replication proteins;SUMO E3 ligases SUMOylate target proteins;NEP/NS2 Interacts with the Cellular Export Machinery;Metabolism of proteins;Influenza Life Cycle;Influenza Infection;Metabolism of RNA;Glycolysis and Gluconeogenesis;Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal;Amplification of signal from the kinetochores;Mitotic Spindle Checkpoint;Cell Cycle Checkpoints;Infectious disease;Leukotriene metabolism;Squalene and cholesterol biosynthesis;Purine metabolism;Vitamin B3 (nicotinate and nicotinamide) metabolism;Vitamin B5 - CoA biosynthesis from pantothenate;Metabolism;Transport of the SLBP independent Mature mRNA;Transport of the SLBP Dependant Mature mRNA;Transport of Mature mRNA Derived from an Intronless Transcript;Transport of Mature mRNAs Derived from Intronless Transcripts;RHO GTPases Activate Formins;Pyrimidine metabolism;SUMOylation;Glycosphingolipid metabolism;Cellular responses to external stimuli;Regulation of Glucokinase by Glucokinase Regulatory Protein;Glycolysis;RHO GTPase Effectors;Phosphatidylinositol phosphate metabolism;Signaling by Rho GTPases;Lysine metabolism;Methionine and cysteine metabolism;Selenoamino acid metabolism;Urea cycle and metabolism of arginine, proline, glutamate, aspartate and asparagine;Aminosugars metabolism;Pentose phosphate pathway;Nuclear Pore Complex (NPC) Disassembly;De novo fatty acid biosynthesis;Glycerophospholipid metabolism;Prostaglandin formation from dihomo gama-linoleic acid;Putative anti-Inflammatory metabolites formation from EPA;Vitamin D3 (cholecalciferol) metabolism;Vitamin E metabolism;tRNA processing in the nucleus;Transport of Mature mRNA derived from an Intron-Containing Transcript;Metabolism of non-coding RNA;Cellular response to heat stress;Nuclear Envelope Breakdown;Mitotic Prophase;Mitotic Prometaphase;Separation of Sister Chromatids;Mitotic Anaphase;Mitotic Metaphase and Anaphase;M Phase;Nuclear import of Rev protein;Glucose metabolism;Transcriptional regulation by small RNAs;Cell Cycle;Resolution of Sister Chromatid Cohesion;Interactions of Vpr with host cellular proteins;Glycine, serine, alanine and threonine metabolism;Cell Cycle, Mitotic;Transport of Mature Transcript to Cytoplasm;Processing of Capped Intron-Containing Pre-mRNA;Arachidonic acid metabolism;Gene Silencing by RNA
(Consensus)
Recessive Scores
- pRec
- 0.121
Intolerance Scores
- loftool
- 0.918
- rvis_EVS
- -1.77
- rvis_percentile_EVS
- 2.32
Haploinsufficiency Scores
- pHI
- 0.870
- hipred
- Y
- hipred_score
- 0.655
- ghis
- 0.688
Essentials
- essential_gene_CRISPR
- E
- essential_gene_CRISPR2
- E
- essential_gene_gene_trap
- E
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.912
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Nup160
- Phenotype
Gene ontology
- Biological process
- mRNA export from nucleus;viral process
- Cellular component
- kinetochore;nuclear envelope;nuclear pore;cytosol;nuclear pore outer ring
- Molecular function
- protein binding;structural constituent of nuclear pore